These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 12417534)
1. Chlamydia pneumoniae-atherosclerosis link: a sound concept in search for clinical relevance. Neumann FJ Circulation; 2002 Nov; 106(19):2414-6. PubMed ID: 12417534 [No Abstract] [Full Text] [Related]
2. Chlamydia pneumoniae, antibiotic treatment, and early atherosclerosis. Liuba P; Pesonen E; Paakkari I Circulation; 2003 Jun; 107(22):e205; author reply e205. PubMed ID: 12796417 [No Abstract] [Full Text] [Related]
3. Antibody levels against Chlamydia pneumoniae and outcome of roxithromycin therapy in patients with acute myocardial infarction. Results from a sub-study of the randomised Antibiotic Therapy in Acute Myocardial Infarction (ANTIBIO) trial. Burkhardt U; Zahn R; Höffler U; Siegler KE; Frilling B; Weber M; Gottwik M; Wehr M; Seidel F; Rosocha S; Tebbe U; Senges J Z Kardiol; 2004 Sep; 93(9):671-8. PubMed ID: 15365734 [TBL] [Abstract][Full Text] [Related]
4. Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae. Rothstein NM; Quinn TC; Madico G; Gaydos CA; Lowenstein CJ J Infect Dis; 2001 Jan; 183(2):232-238. PubMed ID: 11120929 [TBL] [Abstract][Full Text] [Related]
11. Effect of roxithromycin treatment on the endothelial function of Chlamydia pneumoniae seropositive men suffering from peripheral arterial occlusive disease. Wiesli P; Schulthess G Circulation; 2002 Dec; 106(25):e226; author reply e226. PubMed ID: 12485976 [No Abstract] [Full Text] [Related]
12. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Black PN; Blasi F; Jenkins CR; Scicchitano R; Mills GD; Rubinfeld AR; Ruffin RE; Mullins PR; Dangain J; Cooper BC; David DB; Allegra L Am J Respir Crit Care Med; 2001 Aug; 164(4):536-41. PubMed ID: 11520711 [TBL] [Abstract][Full Text] [Related]
17. Progression of peripheral arterial occlusive disease is associated with Chlamydia pneumoniae seropositivity and can be inhibited by antibiotic treatment. Krayenbuehl PA; Wiesli P; Maly FE; Vetter W; Schulthess G Atherosclerosis; 2005 Mar; 179(1):103-10. PubMed ID: 15721015 [TBL] [Abstract][Full Text] [Related]
18. Involvement of Chlamydia pneumoniae in atherosclerosis: more evidence for lack of evidence. Ieven MM; Hoymans VY J Clin Microbiol; 2005 Jan; 43(1):19-24. PubMed ID: 15634945 [No Abstract] [Full Text] [Related]
19. Effects of a brief course of azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome: A double-blind, randomized, placebo-controlled study. Hillis GS; Pearson CV; Harding SA; Sutherland S; Ludlam CA; Marioni JC; Prescott RJ; Fox KA; Flapan AD Am Heart J; 2004 Jul; 148(1):72-9. PubMed ID: 15215794 [TBL] [Abstract][Full Text] [Related]
20. Design of future intervention studies for Chlamydia pneumoniae in atherosclerosis. Grayston JT Am Heart J; 1999 Nov; 138(5 Pt 2):S556-7. PubMed ID: 10539875 [No Abstract] [Full Text] [Related] [Next] [New Search]